metronidazole has been researched along with Community Acquired Infection in 25 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective, multicenter, open-label, randomized controlled trial, 77 patients with mild-to-moderate community-acquired pneumonia with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus metronidazole." | 9.19 | Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. ( Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z, 2014) |
| "In this prospective, multicenter, open-label, randomized controlled trial, 77 patients with mild-to-moderate community-acquired pneumonia with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus metronidazole." | 5.19 | Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors. ( Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z, 2014) |
| "Updated Clostridioides difficile infection (CDI) guidelines published in 2018 recommend vancomycin as first-line treatment." | 4.02 | Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018. ( Adelman, MW; Fridkin, SK; Goodenough, D; Mackey, C; Sefton, S; Thomas, S; Woodworth, MH, 2021) |
| " We believe that the association C3G+aminoglycoside+metronidazole should be used first-line in the pediatric peritonitis in our context." | 3.79 | [Bacteriology of community-acquired peritonitis in children treated in the university hospital of Marrakech]. ( Boutbaoucht, M; Chabaa, L; Mouaffak, Y; Oulad Saiad, M; Salama, T; Soraa, N; Younous, S, 2013) |
| "Moxifloxacin was non-inferior to ceftriaxone/metronidazole in terms of clinical response at test-of-cure in the PP population [clinical cure, 90." | 2.74 | Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. ( Chen, MJ; Hampel, B; Ma, EL; Solomkin, J; Zhao, YP, 2009) |
| " Drug-related adverse events occurred in 18." | 2.71 | Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. ( Choudhri, S; Fogarty, CM; Hamed, K; Katz, E; Larsen, LS; Song, J, 2004) |
| "Forty-five (11%) experienced a recurrence." | 1.51 | Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. ( Alabaster, A; Dang, R; Greenhow, TL; Miranda-Katz, M; Parmar, D, 2019) |
| "Treatment with metronidazole, vancomycin or both for 10 or more days did not prevent recurrences." | 1.39 | Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center. ( Cioara, A; Filipescu, I; Flonta, M; Lupse, M; Todor, N, 2013) |
| "Increased incidence and severity of Clostridium difficile infections (CDIs) is of major concern." | 1.38 | Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. ( Bjornsson, ES; Einarsdottir, R; Gudlaugsdottir, S; Kalaitzakis, E; Sigurdardottir, O; Vesteinsdottir, I, 2012) |
| "As data from Clostridium difficile infection (CDI) in intensive care unit (ICU) are still scarce, our objectives were to assess the morbidity and mortality of ICU-acquired CDI." | 1.38 | Outcome of ICU patients with Clostridium difficile infection. ( Adrie, C; Français, A; Garrouste-Orgeas, M; Laupland, K; Le-Monnier, A; Nguile-Makao, M; Schwebel, C; Tabah, A; Timsit, JF; Vesin, A; Zahar, JR, 2012) |
| "Since 2002, an epidemic of Clostridium difficile infections has occurred in southern Quebec, Canada." | 1.35 | Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. ( Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Labbé, AC | 1 |
| Poirier, L | 1 |
| Maccannell, D | 1 |
| Louie, T | 1 |
| Savoie, M | 1 |
| Béliveau, C | 1 |
| Laverdière, M | 1 |
| Pépin, J | 1 |
| Parmar, D | 1 |
| Dang, R | 1 |
| Miranda-Katz, M | 1 |
| Alabaster, A | 1 |
| Greenhow, TL | 1 |
| Brown, HL | 1 |
| Erickson, GA | 1 |
| Adelman, MW | 1 |
| Goodenough, D | 1 |
| Sefton, S | 1 |
| Mackey, C | 1 |
| Thomas, S | 1 |
| Fridkin, SK | 1 |
| Woodworth, MH | 1 |
| Alvarez, AM | 1 |
| Rathore, MH | 1 |
| Lee, JK | 1 |
| Park, CW | 1 |
| Lee, SH | 1 |
| Kang, HW | 1 |
| Kwon, JH | 1 |
| Kim, JH | 1 |
| Lim, YJ | 1 |
| Kim, ES | 1 |
| Koh, MS | 1 |
| Lee, JH | 1 |
| Lupse, M | 1 |
| Flonta, M | 1 |
| Cioara, A | 1 |
| Filipescu, I | 1 |
| Todor, N | 1 |
| Sun, T | 1 |
| Sun, L | 1 |
| Wang, R | 1 |
| Ren, X | 1 |
| Sui, DJ | 1 |
| Pu, C | 1 |
| Ren, Y | 1 |
| Liu, Y | 1 |
| Yang, Z | 1 |
| Li, F | 1 |
| Miller-Roll, T | 1 |
| Na'amnih, W | 1 |
| Cohen, D | 1 |
| Carmeli, Y | 1 |
| Adler, A | 1 |
| Kim, G | 1 |
| Zhu, NA | 1 |
| Tuduri, I | 1 |
| Solomkin, J | 1 |
| Zhao, YP | 1 |
| Ma, EL | 1 |
| Chen, MJ | 1 |
| Hampel, B | 1 |
| Byun, TJ | 1 |
| Han, DS | 1 |
| Ahn, SB | 1 |
| Cho, HS | 1 |
| Kim, TY | 1 |
| Eun, CS | 1 |
| Jeon, YC | 1 |
| Sohn, JH | 1 |
| Kang, JO | 1 |
| Amezyane, T | 1 |
| Abouzahir, A | 1 |
| El Kharrass, A | 1 |
| Bassou, D | 1 |
| Fatihi, J | 1 |
| Hammi, S | 1 |
| Mahassin, F | 1 |
| Ghafir, D | 1 |
| Ohayon, V | 1 |
| Baker, SS | 1 |
| Faden, H | 1 |
| Sayej, W | 1 |
| Patel, R | 1 |
| Baker, RD | 1 |
| Pant, C | 1 |
| Bass, PF | 1 |
| Vesteinsdottir, I | 1 |
| Gudlaugsdottir, S | 1 |
| Einarsdottir, R | 1 |
| Kalaitzakis, E | 1 |
| Sigurdardottir, O | 1 |
| Bjornsson, ES | 1 |
| Kandel, C | 1 |
| Moayedi, Y | 1 |
| Bunce, PE | 1 |
| Münchhoff, M | 1 |
| Strube, H | 1 |
| Wagener, J | 1 |
| Bogner, JR | 1 |
| Zahar, JR | 1 |
| Schwebel, C | 1 |
| Adrie, C | 1 |
| Garrouste-Orgeas, M | 1 |
| Français, A | 1 |
| Vesin, A | 1 |
| Nguile-Makao, M | 1 |
| Tabah, A | 1 |
| Laupland, K | 1 |
| Le-Monnier, A | 1 |
| Timsit, JF | 1 |
| Mouaffak, Y | 1 |
| Boutbaoucht, M | 1 |
| Soraa, N | 1 |
| Chabaa, L | 1 |
| Salama, T | 1 |
| Oulad Saiad, M | 1 |
| Younous, S | 1 |
| Farrell, S | 1 |
| Milliken, I | 1 |
| Doherty, GM | 1 |
| Murphy, JL | 1 |
| Wootton, SA | 1 |
| McCallion, WA | 1 |
| Katz, E | 1 |
| Larsen, LS | 1 |
| Fogarty, CM | 1 |
| Hamed, K | 1 |
| Song, J | 1 |
| Choudhri, S | 1 |
| Riley, TV | 1 |
| Cooper, M | 1 |
| Bell, B | 1 |
| Golledge, CL | 1 |
| Alcantara, CS | 1 |
| Guerrant, RL | 1 |
2 reviews available for metronidazole and Community Acquired Infection
| Article | Year |
|---|---|
Clostridium difficile Infection in Children.
Topics: Age Factors; Anti-Infective Agents; Child; Child, Preschool; Clostridioides difficile; Clostridium I | 2019 |
Update on Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Disease Outbreaks; Ente | 2000 |
5 trials available for metronidazole and Community Acquired Infection
| Article | Year |
|---|---|
Updates in bacteriological epidemiology of community-acquired severe acute cholangitis and the effectiveness of metronidazole added routinely to the first-line antimicrobial regimen.
Topics: Aged; Anti-Infective Agents; Cholangitis; Cohort Studies; Community-Acquired Infections; Female; Hum | 2013 |
Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolo | 2014 |
Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
Topics: Adult; Anti-Bacterial Agents; Asia; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Doubl | 2009 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired I | 2004 |
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ceftriaxone; Com | 2004 |
18 other studies available for metronidazole and Community Acquired Infection
| Article | Year |
|---|---|
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acqu | 2008 |
Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children.
Topics: Adolescent; California; Child; Child, Preschool; Clostridioides difficile; Clostridium Infections; C | 2019 |
Clostridium difficile infection after antibiotic use.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Antimicrobial Stewardship; Cefpodoxime; Ceftizoxime; Clos | 2020 |
Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cohort Studies | 2021 |
Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides diffi | 2013 |
Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Clostridioides difficile; Clostridium Infections | 2016 |
Community-acquired
Topics: Abdominal Pain; Anti-Bacterial Agents; Clostridioides difficile; Community-Acquired Infections; Diar | 2017 |
Considerations about the article by St. Peter "Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomised trial". J Pediatr Surg 2008;43:981-985.
Topics: Abdominal Abscess; Appendicitis; Cefoxitin; Ceftriaxone; Cefuroxime; Child; Community-Acquired Infec | 2008 |
[Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD)].
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Bacterial Toxins; Cephalospo | 2009 |
[Septic pylephlebitis associated with Enterobacter cloacae septicemia].
Topics: Abdominal Pain; Adult; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Ceftriaxone; Community-Acq | 2010 |
Increasing incidence of community-associated atypical Clostridium difficile disease in children.
Topics: Biopsy, Needle; Child; Child, Preschool; Clostridioides difficile; Clostridium Infections; Colonosco | 2010 |
Comment on: Increasing incidence of community-associated atypical Clostridium difficile disease in children.
Topics: Adult; Anti-Infective Agents; Child; Clostridioides difficile; Clostridium Infections; Community-Acq | 2010 |
Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Tox | 2012 |
A woman with community-acquired Clostridium difficile infection.
Topics: Aged; Anti-Infective Agents; Clostridioides difficile; Community-Acquired Infections; Enterocolitis, | 2012 |
[Clostridium-difficile-colitis: more frequent and more severe].
Topics: Adult; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clos | 2012 |
Outcome of ICU patients with Clostridium difficile infection.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acquired In | 2012 |
[Bacteriology of community-acquired peritonitis in children treated in the university hospital of Marrakech].
Topics: Adolescent; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Child; Child, Preschool; Community | 2013 |
Community-acquired Clostridium difficile-associated diarrhea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Toxins; Child; Child, Preschool; Clostridioide | 1995 |